Superior Toxicology Data from Antikor’s FDC Platform

Tours, France, June 27th, 2017: Antikor Biopharma Limited (Antikor), a leader in advancing antibody fragment-drug conjugates (FDCs), will be presenting new data at the 5th Antibody Industrial Symposium in Tours, France. Dr Yahioglu, Director of Chemistry and co-founder will give an overview of Antikor's unique small-format platform technology that combines the rapid and effective penetration of solid tumours with the faster clearance from normal organs. New data will show that using a highly potent, clinically-validated cytotoxic payload, FDCs are better tolerated and less toxic than antibody-drug conjugates (ADCs) carrying the same quantity of payload. 

Dr Yahioglu commented, "These pivotal data strengthen Antikor's proposition that highly-loaded FDCs can be a superior approach to treating solid tumours, whilst further reducing the risk of liver, renal and haematological toxicities often associated with whole ADCs." Dr Deonarain, Antikor's CEO and CSO commented, "The major issue about applying ADCs successfully in oncology is getting a wide enough therapeutic window in patients. Our data suggest that our approach can open up this window whilst hitting solid tumours more effectively".

For more information about this conference, see

For more information please contact:
Dr Carlos Pittol, Business Development Director,